FAM
ARQT icon

Fred Alger Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Fred Alger Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,304
Closed -$386K – 446
2025
Q4 		$386K Buy
13,304
+2,149
+19% +$55K ﹤0.01% 408
2025
Q3 		$210K Buy
+11,155
New +$176K ﹤0.01% 441
2025
Q2 		– Sell
-36,313
Closed -$568K – 438
2025
Q1 		$568K Buy
+36,313
New +$512K ﹤0.01% 352
2022
Q4 		– Sell
-26,324
Closed -$503K – 519
2022
Q3 		$503K Buy
+26,324
New +$596K ﹤0.01% 395

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fred Alger Management's ARQT Position: Q1 2026 in Review

Fred Alger Management sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 13,304 shares — an estimated $386K sold.

Fred Alger Management first reported a position in ARQT in Q3 2022 and held it in 4 quarters. The position peaked at $568K in Q1 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Fred Alger Management reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Fred Alger Management sold 13,304 Arcutis Biotherapeutics shares in Q1 2026, an estimated $386K.
  • Fred Alger Management first reported a position in Arcutis Biotherapeutics in Q3 2022 and held it in 4 quarters.
  • Fred Alger Management's Arcutis Biotherapeutics position peaked at $568K in Q1 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Fred Alger Management's 13F filing for Q1 2026, filed 15 May 2026.